Effect of Modified Erzhu Erchentang on Major Cardiovascular Risk Factors Caused by Type 2 Diabetes Mellitus with Phlegm Turbidity and Blood Stasis Syndrome

Bing YUN; Ying-ping WU

doi:10.13422/j.cnki.syfjx.20192035

您当前的位置：

首页 >

文章列表页 >

Effect of Modified Erzhu Erchentang on Major Cardiovascular Risk Factors Caused by Type 2 Diabetes Mellitus with Phlegm Turbidity and Blood Stasis Syndrome

Clinic | 更新时间：2021-02-09

- Effect of Modified Erzhu Erchentang on Major Cardiovascular Risk Factors Caused by Type 2 Diabetes Mellitus with Phlegm Turbidity and Blood Stasis Syndrome
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 25, Issue 23, Pages: 104-109(2019)
- 作者机构：
  
  1.三亚市中医院，海南　三亚　 572015；
  2.海南省中医院，海口　 570203
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20192035
  CLC： R25; R587.1; R255; R2544.1
- Received：28 May 2019，
  
  Published Online：28 June 2019，
  
  Published：05 December 2019
- 稿件说明：
移动端阅览
Bing YUN, Ying-ping WU. Effect of Modified Erzhu Erchentang on Major Cardiovascular Risk Factors Caused by Type 2 Diabetes Mellitus with Phlegm Turbidity and Blood Stasis Syndrome[J]. Chinese journal of experimental traditional medical formulae, 2019, 25(23): 104-109.
DOI：

Bing YUN, Ying-ping WU. Effect of Modified Erzhu Erchentang on Major Cardiovascular Risk Factors Caused by Type 2 Diabetes Mellitus with Phlegm Turbidity and Blood Stasis Syndrome[J]. Chinese journal of experimental traditional medical formulae, 2019, 25(23): 104-109. DOI： 10.13422/j.cnki.syfjx.20192035.

摘要

目的：

探讨二术二陈汤加减对2型糖尿病(T2DM)痰浊血瘀证主要心血管高危因素的影响及抗炎效果。

方法：

将142例患者随机按数字表法分为对照组和观察组各72例。对照组采用注射胰岛素或口服降糖药控制血糖；口服拜阿司匹林肠溶片，100 mg/次，1次/d；口服替米沙坦片，40 mg/次，1次/d；口服阿托伐他汀钙片，10 mg/次，1次/d，并进行非药物干预措施。观察组西医处理措施同对照组，并内服二术二陈汤加减治疗，1剂/d，每周服用5 d。两组患者连续治疗24周，再进行24周随访。监测空腹血糖(FPG)，餐后2 h血糖(2 hPG)，糖化血红蛋白(HbA1c)，收缩压(SBP)，舒张压(DBP)，三酰甘油(TG)，总胆固醇(TC)，高密度脂蛋白胆固醇(HLD-C)，低密度脂蛋白胆固醇(LDL-C)；记录48周内的主要心血管事件、脑血管事件和周围血管事件的发生情况；进行治疗前后体质量(BMI)，颈动脉内膜-中层厚度(IMT)，弗明汉高危风险评分(FRS)和腰臀比评价；检测治疗前后降钙素原(PCT)，同型半胱氨酸(Hcy)，超敏C反应蛋白(hs-CRP)，胱抑素C (CysC)和基质金属蛋白酶-9(MMP-9)。

结果：

治疗后观察组患者2 hPG，HbA1c，SBP和DBP均低于对照组(

0.05)；观察组TC，TG，LDL-C均低于对照组(

0.05)，HDL-C高于对照组(

0.05)；在48周的观察期间，观察组患者主要心血管事件的发生率为9.23%，低于对照组的23.44%(

＝4.775，

0.05)；观察组患者主要终点事件的累积发生率为20%，低于对照组的39.06%(

＝5.639，

0.05)；观察组IMT，BMI均低于对照组(

0.05)；经秩和检验分析，观察组患者FRS心血管危险情况轻于对照组(

＝2.165，

0.05)；治疗后观察组患者hs-CRP，PCT，Hcy，CysC和MMP-9均低于对照组(

0.01)。

结论：

在常规西医综合治疗的基础上，采用内服二术二陈汤加减治疗T2DM痰浊血瘀证患者，可减轻血清炎症因子，能有效控制T2DM患者的心血管疾病高危因素，从而起到了降低主要心血管事件发生的效果。

Abstract

Objective:

To discuss the efficacy of Erzhu Erchentang on major cardiovascular risk factors caused by type 2 diabetes mellitus (T2DM)with phlegm turbidity and blood stasis syndrome

and its anti-inflammatory effect.

Method:

One hundred and forty-two patients were randomly divided into control group and observation group by random number table. Patients in control group got insulin or oral hypoglycemic drugs for controlling blood sugar

aspirin enteric-coated tablets

100 mg/time

1 time/day

telmisartan tablets

40 mg/time

1 time/day

atorvastatin

10 mg/time

1 time/day

and non-drug interventions. In addition to the therapy of control group

patients in observation group were also given modified Erzhu Erchentang

1 dose/day

5 times/week. The course of treatment was 24 weeks. And a 24-week follow-up was recorded. And levels of fasting blood glucose (FPG)

2 h postprandial blood glucose (2 hPG)

glycosylated hemoglobin (HbA1c)

systolic blood pressure (SBP)

diastolic blood pressure (DBP)

triglyceride (TG)

total cholesterol (TC)

high-density lipoprotein cholesterol (HLD-C) and low-density lipoprotein (LDL-C) were detected. And the occurrence of major cardiovascular events

cerebrovascular events and peripheral vascular events were recorded. Before and after treatment

levels of body mass index (BMI)

carotid intima-media thickness (IMT)

framingham risk (FRS) and waist-hip ratio (WHR) were assessed. And procalcitonin (PCT)

homocysteine (Hcy)

hypersensitive C-reactive protein (hs-CRP)

cystatin C (CysC) and matrix metalloproteinase-9 (MMP-9) were measured.

Result:

After treatment

levels of 2 hPG

HbA1c

SBP

DBP

LDL-C

IMT and BMI in observation group were lower than those in control group (

0.05)

while level of HDL-C was higher than that in control group (

0.05). During 48 hours of observation

the incidence of major cardiovascular events in observation group was 9.23%

which was lower than 23.44% in control group (

=4.775

0.05). The cumulative incidence of major endpoint events in observation group was 20%

which was lower than 39.06% in control group (

=5.639

0.05). According to rank sum test

cardiovascular risk in observation group was lighter than that in control group (

=2.165

0.05). And levels of hs-CRP

PCT

Hcy

CysC and MMP-9 were all lower than those in control group (

0.01).

Conclusion:

In addition to the comprehensive therapy of conventional western medicine

modified Erzhu Erchentang can increase the reduce serum inflammatory factors and control the high risk factors of cardiovascular disease of patients with T2DM

so as to reduce the major cardiovascular events.

关键词

Keywords

references

中华医学会糖尿病学分会．中国2型糖尿病防治指南(2017年版) [J]．中华糖尿病杂志， 2018 ， 10 ( 1 )： 4 - 67 ．

Neumiller J J , Setter S M . Review of Linagliptin for the treatment of type 2 diabetes mellitus [J]. Clin Ther , 2012 , 34 ( 5 ): 993 - 1005 .

JI L , HU D , PAN C , et al . Primacy of the 3 B approach to control risk factors for cardiovascular disease in type 2 diabetes patients [J]. Am J Med , 2013 , 126 ( 10 ): 925.e11 - 925.e22 .

庄宁，张建东，万钢，等． 2型糖尿病管理八年联合达标对心血管事件及全因死亡的影响研究 [J]．中国全科医学， 2017 ， 20 ( 25 )： 3109 - 3116 ．

中华中医药学会糖尿病分会．糖尿病中医诊疗标准 [J]．世界中西医结合杂志， 2011 ， 6 ( 6 )： 540 - 547 ．

王志宏，季旭明，吴智春，等．苍白二陈汤对代谢综合征大鼠血脂水平和主动脉ICAM1表达的影响 [J]．中华中医药学刊， 2013 ， 31 ( 6 )： 1243-1245，1474 ．

刘姿瑶，朱晓明，高小宇，等．二陈汤在心脑系统疾病中运用与探讨 [J]．辽宁中医药大学学报， 2018 ， 20 ( 7 )： 183 - 186 ．

中华医学会糖尿病学分会．中国2型糖尿病防治指南(2013年版) [J]．中国糖尿病杂志， 2014 ， 30 ( 8 )： 893 - 942 ．

中国成人血脂异常防治指南修订联合委员会．中国成人血脂异常防治指南(2016年修订版) [J]．中国循环杂志， 2016 ， 31 ( 10 )： 937 - 953 ．

孙奥松． CT冠状动脉钙化积分与传统危险积分临床应用的对比 [J]．实用医药杂志， 2017 ， 34 ( 2 )： 139 - 141 ．

常红叶，齐力，夏薇．糖化血红蛋白和血小板活化标志物检测在糖尿病并发症及心脑血管疾病诊断中的应用 [J]．中国实验诊断学， 2017 ， 21 ( 10 )： 1775 - 1777 ．

尹纯，孙艺红． 2型糖尿病血脂异常及治疗 [J]．心血管病学进展， 2017 ， 38 ( 5 )： 488 - 492 ．

张愿，谢红艳，谢春光．益气健脾升阳化浊法防治糖尿病血管病变 [J]．光明中医， 2017 ， 32 ( 16 )： 2330 - 2331 ．

张颖，张明雪．冠心病合并糖尿病从痰瘀论治 [J]．辽宁中医药大学学报， 2016 ， 18 ( 4 )： 107 - 109 ．

张蕊，何建秋，葛晓春，等．颈动脉内-中膜厚度和血浆同型半胱氨酸与2型糖尿病大血管并发症的关系 [J]．新疆医科大学学报， 2018 ， 41 ( 11 )： 1380 - 1383 ．

姬劲锐，刘恒亮，索森森，等．降钙素原及同型半胱氨酸与2型糖尿病合并冠心病患者冠状动脉病变的相关性 [J]．临床心血管病杂志， 2017 ， 33 ( 3 )： 235 - 238 ．

王莹，王爱华，田甜． 2型糖尿病合并动脉粥样硬化中内皮素-1，脂联素，C反应蛋白的水平及相关代谢指标的相关性 [J]．广东医学， 2019 ， 40 ( 7 )： 1020 - 1024 ．

赵坤，蔡双兵，肖丹，等．老年糖尿病患者血清胱抑素C水平与原发性高血压相关性研究 [J]．中华老年心脑血管病杂志， 2015 ， 17 ( 4 )： 357 - 360 ．

陈晓文，李竞．基质金属蛋白酶9与糖尿病血管病变的关系 [J]．医学综述， 2016 ， 22 ( 5 )： 954 - 957 ．

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Effect of Puerariae Lobatae Radix on Expression of Endoplasmic Reticulum Stress Related Proteins GRP78 and ATF6 in T2DM Rats

Effect of Modified Yuquanwan Combined with Taohong Siwutang on Major Cardiovascular Risk Factors of Patients with Type 2 Diabetes

Effect of Coptidis Rhizoma on Endoplasmic Reticulum Stress Pathway PERK/ATF4/CHOP in Pancreas of Rats with Type 2 Diabetes Mellitus

Application of Puerariae Lobatae Radix in Treatment of Type 2 Diabetes Mellitus： A Review

Clinical Efficacy of Early Application of Da Xianxiongtang in Mitigating Progression of Acute Pancreatitis

Related Author

Lu-yu ZHANG

Yu YOU

Rong-hua LIU

Hao-kun LIU

Hai-bei WANG

Hai-hua HUANG

Yu-hui LIU

Yan-hong LI

Related Institution

School of Pharmacy，Jiangxi University of Traditional Chinese Medicine

The First Affiliated Hospital of Nanchang University

Gannan Medical College

Wuchang Hospital Affiliated to Wuhan University of Science and Technology

The First Affiliated Hospital of Guangzhou University of Chinese Medicine

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰